For FY14 , Alembic Pharmaceuticals net profit surged to Rs235.50 crore on robust growth of its international generic business
Alembic Pharmaceuticals Ltd reported a 43% higher net profit during its full year results due to 99% growth in its international generic business.
For the 12 months to end-March, Alembic Pharmaceuticals said its net profit increased 43% to Rs235.50 crore from Rs165.23 crore while its total revenues, including sales, grew 22% to Rs1,868.4 crore from Rs1,526 crore a year ago period.
During FY14, Alembic Pharmaceuticals' international branded business grew 32% to Rs73.60 crore while, international generic formulations business grew 99% to Rs468.4.
Alembic Pharmaceuticals said in FY14, its India branded formulations business grew 14% to Rs850.6 crore, however its Indian generic business fell 4% to Rs120.71 crore.
In its quarter to end-March Alembic Pharmaceuticals said its net profit grew 40% to Rs61.3 crore from Rs43.7 crore while its total revenues, including sales, grew 23% to Rs465.2 crore from Rs378.4 crore a year ago period.
During FY14 Alembic Pharmaceuticals filed four abbreviated new drug application (ANDA) applications taking its cumulative ANDA filings to 61. It received 8 ANDA approvals during FY14 taking its cumulative to 32 ANDA approvals.
Alembic Pharmaceuticals declared a dividend of Rs3 per share.
At 2.33pm Tuesday, Alembic Pharmaceuticals was trading 2.8% up at Rs288 on the BSE, while the 30-share Sensex was flat at 22,522.
For more stock results, check out this page
Inside story of the National Stock Exchange’s amazing success, leading to hubris, regulatory capture and algo scam
Fiercely independent and pro-consumer information on personal finance.
1-year online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.
Fiercely independent and pro-consumer information on personal finance.
30-day online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.
Fiercely independent and pro-consumer information on personal finance.
Complete access to Moneylife archives since inception ( till the date of your subscription )
